Nasdaq:ALKS
Alkermes plc.
A specialized pharmaceutical innovator delivering breakthrough psychiatric and metabolic treatments with a robust balance sheet and diversified revenue streams.
Key Metrics
Investment Thesis
Bull Case
Alkermes offers an attractive investment opportunity due to its substantial cash reserves of $1.12B which provide a defensive buffer against market volatility and fund future growth initiatives. The company's diversified portfolio of innovative CNS and metabolic drugs positions it well to capture growing global demand for treatments in these therapeutic areas. Strong operating margins and consistent profitability suggest the management team can effectively navigate the complex pharmaceutical landscape.
Bear Case
Investors should be cautious about the company's revenue contraction from $1.66B in 2023 to $1.48B, which may indicate market saturation or competitive pressures on its core products. The reliance on a concentrated portfolio of specialty drugs creates vulnerability if key patents expire or if formulary positions are challenged by lower-cost alternatives. High operating expenses of $1.03B relative to revenue could compress margins further if sales growth does not keep pace with inflation and R&D costs.
About Alkermes plc.
Alkermes plc. is a leading pharmaceutical company focused on discovering and commercializing innovative therapies primarily for psychiatric disorders and obesity, serving patients in the United States and international markets through its proprietary formulations like Spravato and Contrave. The company leverages its expertise in controlled-release delivery systems to provide sustained-action treatments that improve patient compliance and outcomes. With strong cash generation capabilities, Alkermes continues to invest heavily in research and development to expand its therapeutic portfolio.
Analysis
Management Discussion
Alkermes reported a net profit of $241.7M for the latest year, representing a slight decline from the previous year's $367.1M despite revenue growth to $1.48B from $1.56B. The company maintained strong operational cash flow of $520.8M while investing $40.4M in capital expenditures and $324M in research and development. This financial profile indicates a mature business with solid profitability but requires careful management of revenue mix as it navigates potential product lifecycle transitions.
Industry Overview
The global pharmaceutical sector is experiencing significant transformation driven by advancements in neuroscience, metabolic health, and personalized medicine technologies. Companies in this space face intense competition for market share while navigating complex regulatory environments and evolving healthcare payment models. Alkermes operates within a niche focused on controlled-release delivery systems that offer distinct advantages over immediate-release formulations.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.11B | $1.66B | $1.56B | $1.48B |
| Cost of Revenue | $218.1M | $253.0M | $245.3M | $196.5M |
| Gross Profit | $893.7M | $1.41B | $1.31B | $1.28B |
| Operating Expenses | $1.04B | $996.2M | $891.7M | $1.03B |
| Operating Income | $-142.3M | $414.1M | $420.6M | $254.0M |
| R&D | $393.8M | $270.8M | $245.3M | $324.0M |
| G&A | $605.7M | $689.8M | $199.0M | $221.5M |
| Marketing | — | — | $446.2M | $480.0M |
| Stock-Based Comp | $94.3M | $100.9M | $96.6M | $98.7M |
| D&A | $77.9M | $74.9M | $28.5M | $27.2M |
| Depreciation | $41.7M | $25.7M | $27.4M | $31.1M |
| Amortization | $36.4M | $35.7M | $1.1M | — |
| Other OpEx | $36.4M | $35.7M | $1.1M | $0 |
| Non-Operating Income | $-25.0M | $7.4M | $23.1M | $37.5M |
| Interest Expense | $13.0M | $23.0M | — | — |
| Interest Income | $7.6M | $30.9M | $42.5M | $45.3M |
| Pre-Tax Income | $-167.3M | $421.5M | $443.8M | $291.4M |
| Income Tax | $-9.0M | $-97.6M | $71.6M | $49.8M |
| Continuing Ops | $-158.3M | $519.2M | $372.1M | $241.7M |
| Discontinued Ops | $0 | $-163.4M | $-5.1M | $0 |
| Net Income | $-158.3M | $355.8M | $367.1M | $241.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-158.3M | $355.8M | $367.1M | $241.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.13B | $1.49B | $1.42B | $1.93B |
| Cash & Equivalents | $292.5M | $457.5M | $291.1M | $388.6M |
| Inventory | $181.4M | $186.4M | $182.9M | $196.6M |
| Prepaid Expenses | $43.5M | $98.2M | $91.3M | $79.1M |
| Other Current Assets | $612.9M | $743.5M | $850.0M | $1.26B |
| Long-Term Assets | $833.7M | $650.7M | $640.2M | $557.8M |
| PP&E (Net) | $325.4M | $226.9M | $227.6M | $221.7M |
| Goodwill | $92.9M | $83.0M | $83.0M | $83.0M |
| Operating Leases | $115.9M | $91.5M | $84.2M | $77.2M |
| LT Investments | $131.6M | $39.9M | $73.1M | $145.0K |
| Other LT Assets | $168.0M | $209.4M | $172.2M | $175.7M |
| Total Assets | $1.96B | $2.14B | $2.06B | $2.49B |
| Current Liabilities | $497.7M | $520.2M | $465.2M | $543.4M |
| Accounts Payable | $32.8M | $65.6M | $45.6M | $108.0M |
| Current Debt | $3.0M | $3.0M | — | — |
| Current Leases | $15.7M | $5.7M | $6.2M | $6.7M |
| Deferred Revenue | $6.8M | $2.7M | $1.2M | $0 |
| Other Current Liab | $439.4M | $443.1M | $412.2M | $428.7M |
| Long-Term Liabilities | $422.5M | $413.3M | $125.4M | $124.3M |
| Long-Term Debt | $290.3M | $287.7M | — | — |
| LT Operating Leases | $89.8M | $75.7M | $69.4M | $63.3M |
| Other LT Liab | $42.4M | $49.9M | $56.0M | $61.0M |
| Total Liabilities | $920.2M | $933.5M | $590.6M | $667.7M |
| Shareholders' Equity | $1.04B | $1.20B | $1.46B | $1.82B |
| Retained Earnings | $-1.70B | $-1.34B | $-976.5M | $-734.8M |
| AOCI | $-10.9M | $-3.1M | $-2.0M | $-2.1M |
| Total L&E | $1.96B | $2.14B | $2.06B | $2.49B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-158.3M | $355.8M | $367.1M | $241.7M |
| Non-Cash Adjustments | $151.5M | $-54.7M | $74.1M | $216.4M |
| Working Capital Changes | $27.8M | $100.3M | $-2.1M | $62.7M |
| Cash from Operations | $21.0M | $401.4M | $439.1M | $520.8M |
| Capital Expenditures | $38.3M | $48.0M | $33.5M | $40.4M |
| Cash from Investing | $-64.5M | $53.4M | $-111.3M | $295.5M |
| Debt Repayments | $3.0M | $3.0M | $2.2M | — |
| Share Buybacks | — | — | $200.3M | — |
| Cash from Financing | $-1.6M | $-289.7M | $-494.1M | $12.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-45.1M | $165.0M | $-166.3M | $828.6M |
| Beginning Cash | $337.5M | $292.5M | $457.5M | $291.1M |
| Ending Cash | $292.5M | $457.5M | $291.1M | $1.12B |
Frequently Asked Questions
How does Alkermes plc. make money?
Core commercial revenues are driven by Spravato for major depressive disorder and Contrave for chronic weight management, supported by other CNS therapies and legacy products. The company generates income through product sales in the US and international markets, while R&D expenses reflect its focus on next-generation formulations and new indications.
What are the main risks for ALKS?
Reliance on a few blockbuster products like Spravato and Contrave exposes the company to patent cliffs and generic competition that could significantly impact future revenue. The pharmaceutical industry faces intense regulatory scrutiny and potential changes in reimbursement policies that could affect pricing power and market access. Ongoing high R&D expenditures of approximately $324 million carry the risk of failure in clinical trials or delays in product approvals.
What is ALKS's competitive advantage?
Alkermes possesses a unique proprietary technology platform for controlled-release delivery systems that differentiates its products from competitors. Its strong balance sheet with over $1.1 billion in cash provides significant flexibility for strategic acquisitions and R&D investments without immediate dilution concerns. The company benefits from established payer relationships and formulary placements for its high-value specialty products.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.